Premium
Failure of omalizumab in cholinergic urticaria
Author(s) -
Sabroe R. A.
Publication year - 2010
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2009.03748.x
Subject(s) - omalizumab , medicine , cholinergic , chronic urticaria , asthma , disease , monoclonal , dermatology , monoclonal antibody , immunoglobulin e , immunology , antibody
Summary Cholinergic urticaria is one of the more common physical urticarias. Although it is often fairly mild, severe treatment‐resistant disease may occur, with significant associated disability. Omalizumab, a monoclonal IgG anti‐IgE antibody licensed for use in severe asthma, has recently been used successfully in several types of urticaria, including in one case of cholinergic urticaria. This paper reports a patient with severe cholinergic urticaria, unresponsive to antihistamines and multiple other treatments, whose disease was also unresponsive to omalizumab.